Cargando…
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways with...
Autores principales: | Shen, Hua, Wang, Gao-Chan, Li, Xiang, Ge, Xin, Wang, Meng, Shi, Zhu-Mei, Bhardwaj, Vikas, Wang, Zi-Xuan, Zinner, Ralph G., Peiper, Stephen C., Aplin, Andrew E., Jiang, Bing-Hua, He, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718330/ https://www.ncbi.nlm.nih.gov/pubmed/33037411 http://dx.doi.org/10.1038/s41388-020-01497-4 |
Ejemplares similares
-
Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014) -
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018) -
Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020) -
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021) -
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)